Abstract: We report ad iscovery that personal glucose meters (PGMs) can give ad ose-dependent response to nicotinamide coenzymes,such as the reduced form of nicotinamide adenine dinucleotide (NADH). We have developed methods that take advantage of this discovery to perform one-step homogeneous assays of many non-glucose targets that are difficult to recognizebyDNAzymes,aptamers,orantibodies,and without the need for conjugation and multiple steps of sample dilution, separation, or fluid manipulation. The methods are based on the target-induced consumption or production of NADH through cascade enzymatic reactions.S imultaneous monitoring of the glucose and l-lactate levels in human plasma from patients with diabetes is demonstrated and the results are comparable to those from current standardtest methods.Since alarge number of commercially available enzymatic assaykits utilize NADH in their detection, this discovery will allowt he transformation of almost all of these clinical lab tests into POC tests that use aPGM.
Point-of-care (POC) devices that allow rapid, on-site,a nd affordable detection and monitoring of health biomarkers at home or away from clinical labs have received increasing attention in modern medicine.
[1] Despite their importance, few POC devices are commercially available,p artly because of high research and development costs,a nd successfully developed devices are often dedicated instruments that can detect as ingle or limited targets.T oo vercome these limitations,w ea nd others have taken advantage of existing POC devices,s uch as personal glucose meters (PGMs), and adapted them to measure aw ide range of targets. [2] In so doing, we can bypass the costly development process and use asingle device to measure many targets. [3] Akey challenge in this endeavor is to find away to translate recognition of many targets into an easily measurable signal using aPGM. To meet the challenge,w ea nd others have demonstrated coupling of target binding by DNAzymes,a ptamers,D NA,a nd antibodies with enzymes such as invertase or glucoamylase,which can convert sugars that do not register ar eading on aP GM (e.g.,sucrose and amylose) into glucose that is detectable by using aP GM.
Despite substantial progress made in the last few years by using the PGM to quantify non-glucose targets,there are still several issues that need to be addressed before its practical applications in clinical diagnostics is realized. Firstly,t he majority of these systems are limited to those targets that can be recognized by DNAzymes,aptamers,DNA,orantibodies. Some progress has been made towards the use of PGMs for enzyme activity applications; [2d, 4] however, these methods either require sophisticated syntheses of the enzyme substrates that covalently link to glucose,orisnot transferable to many targets as ag eneral strategy.S econdly,t hese applications require conjugation of the recognition elements (e.g., aptamers or antibodies) with the enzymes through chemical/ biochemical reactions that may affect the structure and activity of the enzyme.
[2c,h,l] Thirdly,m any methods involve multiple sequential steps,including affinity capture on asolid surface (e.g.,magnetic materials,electrodes,ormicroplates), physical separation, and chemical or biochemical signal amplifications, [2c,e-l,n] making them less user-friendly for POC applications.F inally,t he interference of endogenous glucose to PGM readout in clinical samples is inevitable.Acommon strategy to circumvent this problem is to measure and subtract the background glucose signal from the signal obtained in the subsequent test.
[2f-j] However, when the background signal is much larger than the signal generated by the target, especially for the detection of at race amount of the target, the background subtraction method would be inaccurate.T o address these issues,wehave explored anew PGM function, namely,d ose-dependent response of nicotinamide coenzymes,s uch as the reduced form of nicotinamide adenine dinucleotide (NADH), and have taken advantage of this discovery to demonstrate an ovel PGM-based detection of aw ide range of targets in as ingle step and without the need for conjugation. We have also overcome the background glucose issue by employing an enzyme that can efficiently remove the endogenous glucose during the PGM assay.
After decades of development, the majority of PGMs are based on an electrochemical reaction wherein the glucose is allowed to react with an enzyme electrode and the resulting change in the current/voltage is measured. [5] To facilitate the electron transfer to the electrode,m ost glucose test strips utilize redox mediators that couple the enzymatic reactions with electrochemical signals,t hereby generating ac urrent detected by aP GM ( Figure S1 in the Supporting Information). Since the signal transduction is related to the redox process of the mediator,w eh ypothesized that such aP GM system might also possess the ability to measure non-glucose species that could trigger the redox reaction of mediators located on the strips,w ithout the need to transform the binding of non-glucose targets into detectable glucose. [2c-l] In so doing, we would expand the utility of PGM to even wider range of targets.
To test this hypothesis,w ec hose the nicotinamide coenzymes (e.g., NADH) as an ideal candidate,b ecause the NADH/NAD + redox pair ( Figure 1A )i su biquitous in all living systems and is required for the reactions of more than 450 oxidoreductases. [6] As shown in Figure 1B ,t he PGM shows ad ose-dependent linear response to NADH in the range of 1.0-15.0 mm,w hile neither 100 mm NAD + nor endogenous NADH in serum samples,r eported to be in the range of 5-12 mm, [7] registered any reading on the PGM. The detection limit of NADH is 0.73 mm,w hich is compatible to that of glucose detection using the same glucose meter strips ( Figure S2 ). To further verify the NADH-triggered redox reaction on the glucose meter strips,w ec onnected the strips with an electrochemical station (CH Instruments,Inc.,USA), and monitored the cyclic voltammetric signals of the strips in the absence or presence of NADH, glucose,N AD + ,a nd H 2 O 2 ,respectively ( Figure S3 ). Not surprisingly,the presence of either NADH or glucose resulted in enhanced signal response,w hile NAD + produced negligible change.I n addition, the presence of H 2 O 2 resulted in aslightly decreased electrocatalytic signal, which resulted in no reading on the PGM. These results suggest that the mediator can oxidize NADH to NAD + ,w hile the mediator itself is reduced;s uch ar educed mediator can then be re-oxidized at the electrode surface,p roducing an enhanced current signal that can be detected by the PGM ( Figure 1C ). Although other species (e.g.,F e 2+ )can react with the mediator and contribute to the PGM readout, we found that these species could generate aP GM signal only at ac oncentration above 1.0 mm (Figure S4 ), which is much higher than known concentrations of these species in clinical samples.
To evaluate the performance of this NADH/PGM system, we first investigated its use for the quantitative detection of llactate in plasma, which is measured routinely for clinical diagnosis and treatment of lactic acidosis in patients with diabetes, [8] monitoring tissue hypoxia and strenuous physical exertion, [9] and diagnosis of hyperlactatemia. [10] We employed lactate oxidase (LOx) and lactate dehydrogenase (LDH). [8, 11] As shown in Figure 1D ,inthe presence of sufficient amounts of NADH and oxygen, the l-lactate can be oxidized to pyruvate by LOx and the pyruvate formed can be subsequently reduced back to l-lactate by LDH. This enzymatic cascade reactions can keep the l-lactate concentration constant, so that the l-lactate serves not only as ad etection target but also as an intermediate catalyst to amplify the signal. As aresult, atrace amount of l-lactate can result in the consumption of high concentration of NADH within as hort period of time,a nd thus increase the sensitivity by several orders of magnitude.
Am ajor challenge of this NADH/PGM method is interference from endogenous glucose.T or emove the interference,w ee mployed another enzyme,h exokinase, which can catalyze the conversion of glucose to glucose-6-phosphate that is known to register no reading on the PGM. To test the feasibility of this method in l-lactate detection, 50 UmL À1 hexokinase was added into 200 mm HEPES buffer containing either 20 mm glucose or 20 mm NADH. Ar apid decrease of the PGM signal for glucose was observed ( Figure S5 ), while the PGM signal for NADH showed negligible change.E ncouraged by this result, we further applied this method to glucose removal in human serum. As shown in Figure 2A ,the background glucose signal in serum decreased after the addition of hexokinase and reached a" LO" readout in 5min. In contrast, the NADH in human serum, after glucose is depleted, gave ac onstant PGM readout. These results indicate that hexokinase can remove the background glucose signal efficiently and, more importantly,s how no interference with the NADH signal.
To demonstrate the multienzymatic cascade reaction shown in Figure 1D for l-lactate detection using NADH as PGM readout, 8 mLo fr eagent A( 10 mm NADH, 8UmL
À1
LOx, 40 UmL À1 LDH, 50 mm ATP, 50 UmL À1 hexokinase was added into 2 mLo fr eagent B( l-lactate), and at imedependent NADH readout was monitored ( Figure 2B ). In the presence of 0.125 mml-lactate,t he NADH consumption rate was calculated to be À12.3 mg dL À1 min
,w hich indicated ar apid PGM response toward l-lactate arising from enzymatic lactate recycling reactions.The performance of the NADH/PGM system for lactate detection was then investigated in HEPES buffer ( Figure 3A) . In asingle step,8mLof reagent Aw as directly added into the lactate sample in HEPES buffer, and reacted at room temperature for 10 min. Aq uantitative relationship is established between the PGM signal and l-lactate concentration in HEPES buffer in the range 0-2.0 mm,with adetection limit of 0.034 mm according to the definition of detection limit = 3s b /slope (s b is the standard deviation of the blank samples). Such ao ne-step homogeneous assay holds great promise for POC detection at home.
To demonstrate the compatibility of our method in complex biological samples,w ef urther tested the l-lactate detection in 100 %h uman serum and then calf blood (Figure 3A) . First, ac ontrol experiment was performed to examine whether the calf blood interferes with the added NADH. Not surprisingly,i nt he absence of LDH and LOx, the NADH consumption rate was calculated to be À0.1 mg dL À1 min À1 ( Figure S6 ), much lower than that of 0.125 mml -lactate in the presence of LDH and LOx (Figure 2B) , thus indicating that the blood components showed negligible contribution to the NADH consumption in our method. Then, as eries of human serum and calf blood samples were spiked with different concentrations of llactate.U nder the same condition, the PGM signal showed similar trends with increasing concentrations of l-lactate in serum and blood ( Figure 3A) , with detection limits of 0.14 mm and 0.11 mm,r espectively.T he lactate in calf blood samples showed ah igher saturation PGM signal than in HEPES buffer and human serum samples because the calf blood contained alarger amount of hemoglobin, the binding of O 2 to which may affect the kinetics of the oxygen-sensitive multienzymatic cascade reaction shown in Figure 1D .I n applications,acalibration using different samples is required to take into these different effects into consideration.
Since different users may have different concentrations of lactate in different samples,i ti si mportant to tune the dynamic range of the detection to match those in the user samples.T he lactate detection in human serum was tuned from 0-2.5 mm to 0-25.0 mm by simply adjusting the ratio between NADH, LOx, and LDH ( Figure S7 ). To verify the accuracy and reliability of our system compared to traditional spectroscopic methods,t he consumption of NADH in the presence of lactate,L DH, and LOx in human serum was recorded at the 340 nm by using aU V/Vis spectrometer ( Figure S8 ). Agood correlation between the two methods was observed ( Figure S9 ). These results indicated that other components of the human serum or calf blood did not interfere significantly with the NADH signal.
Encouraged by the above successful l-lactate assays in biological samples,w ef urther conducted similar tests in human plasma samples collected from diabetic patients during clinical treatment to demonstrate the utility of our method for clinical diagnosis.F igure 3B shows the comparison of the NADH/PGM method for l-lactate detection with the standard clinical method that uses aY SI lactate analyzer. At otal of 36 samples in human plasma were evaluated. A strong positive correlation between these two methods was found, with aslope of 1.05 AE 0.03 and acorrelation coefficient of 0.97, thus demonstrating that the results from the two methods were consistent to within experimental error. These results confirm that the accuracyofour NADH/PGM method is as good as that of the clinical l-lactate detection method, thus confirming the suitability and reliability of the NADH/ PGM as an alternative test method for POC detection.
Furthermore,wetook the advantage of the NADH/PGM system to demonstrate simultaneous monitor of the glucose and l-lactate levels in human plasma from patients with diabetes during clinical treatment, and ag ood correlation between NADH/PGM method and current standard clinical test method for both glucose and l-lactate monitoring was obtained ( Figure S10 ). Given the facile integration of various NAD + -dependent enzymes into the NADH/PGM system, the proposed method holds great promise to provide patients with as ingle-device solution that can quantitatively monitor multiple biomarkers at home.
To demonstrate that our NADH/PGM method can be generally applied to other targets,w ed esigned as ensor for glucose-6-phosphate dehydrogenase (G6PD), which is the most common human enzyme defect, affecting approximately 400 million people worldwide. [12] Since G6PD can convert glucose-6-phosphate (G6P) to 6-phosphogluconolactone, which couples the reduction of NAD + to NADH (Figure 4 inset), as ingle-step mixing of G6PD with G6P and NAD + resulted in the production of NADH at ar ate of 16.4 mg dL À1 min À1 ( Figure S11 ). As ar esult, the NADH/ PGM system allowed the quantitative analysis of G6PD activity in HEPES buffer and human blood (Figure 4) , with ad etection limit of 0.05 UmL À1 and 0.10 UmL À1 ,r espec- Figure 3 . A) l-lactate detectioni nHEPES buffer,100 %human serum, and calf blood by using the NADH/PGM system. DP is defined as PGM signal decrease after adding lactate to reagent A. B) Comparison of the NADH/PGM method with the standard clinical method using aYSI lactate analyzer for l-lactate detection based on 36 samples in human plasma.
tively.These detection limits are lower than the normal G6PD level (0.49 to 2.8 UmL À1 ,c alculated from 0.135 gmL À1 hemoglobin), [13a] thus making it possible for potential application in G6PD deficiencydiagnosis.
In summary,w eh ave designed as imple and general method, based on the newly discovered capability of PGM to detect NADH, that allows rapid, portable,u ser-friendly,a nd cost-effective quantification of aw ide range of non-glucose targets,i ncluding those that are difficult to be recognized by DNAzymes,a ptamers,D NA,a nd antibodies.C ritical to the success of the method described in this work is the employment of aseries of enzymatic reactions to link the target to the consumption of NADH in order to perform the test using aPGM. Our design allows simultaneous target detection and endogenous glucose removal homogeneously in one single step,b ya pplying as mall amount of reagent directly into clinical samples,t hus avoiding any sample dilution, separation, or fluid manipulation steps.A lthough UV absorption and fluorescence of NADH have been used for the standard enzyme activity and metabolite assays when the NADH is formed or consumed in the presence of these targets,f ew portable devices that take advantage of these reactions suitable for POC applications are commercially available. Moreover,the optical signals of NADH in the standard assays are vulnerable to interference from colored species in the clinical samples (e.g.,hemoglobin in blood). Procedures used in clinical labs to remove the colored species,s uch as centrifugation or ultrafiltration are not suitable for POC applications.However,since multiple enzymes are employed in our system, each enzyme activity has to be carefully calibrated in order to ensure accurate results and reproducibility.D espite this issue,s ince NADH is af unctionally important metabolite required to support numerous cellular processes,and since alarge number of commercially available enzymatic assay kits in the clinical labs utilize NADH in their detection, [13b] the newly discovered function of PGM can be easily expanded for the monitoring of awide range of targets when coupled with various NADH-dependent enzymes.B y converting the PGM into an all-purpose platform to monitor other biomarkers using NADH, this method opens another new avenue to bypassing the costly medical device development process,t hus allowing millions of people to use the small, portable,a nd affordable PGMs they already own to regularly monitor, literally at their fingertips,n ot only their blood glucose levels,b ut also other relevant biomarkers by using as ingle monitoring device.
